26 November 2019
Visiongain has published a new pharma report Anti-Idiopathic Pulmonary Fibrosis Drugs Market: Forecast Antifibrotics, Tyrosine Kinase Inhibitors, Anti-inflammatory Drugs, Immunosuppressants, Other MoA, Innovator Drugs.
The global anti-idiopathic pulmonary fibrosis drugs market is expected to grow at a CAGR of 16.7% in the first half of the forecast period. In 2018, the anti-fibrotics held the largest market share (51%) followed by the tyrosine kinase inhibitors.
The lead analyst commented that "During the forecast period, the global market is driven by the raising prevalence and incidence of IPF patients, expected launch of novel therapies, special regulatory (Orphan and Fast-track) designations for pipeline molecules, increased understanding of disease pathogenesis, and limited number of current players. However, the global market is curtailed by various challenges during the forecast period with use of off-label drugs, availability of non-pharmacological therapies, and lack of proper diagnosis techniques, as well as absence of highly efficacious & safe drugs."
Leading companies featured in this report include Boehringer Ingelheim, Cipla Limited, Galapagos NV, MediciNova Inc., Merck & Co., Roche, Shionogi & Co. Ltd. and other companies.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Some of the major factors fuelling the growth of global market include significant advantages associated with PIM solutions and inclination towards centralized models among across pharma sector.
19 October 2020
The coronavirus outbreak has negatively impacted all the economies and industries across the globe. Hence, for the next 1-2 years, the global respiratory drug delivery market is expected to take a hit.
12 October 2020
We predict strong revenue growth through to 2030. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
02 October 2020
The development of mRNA vaccines is driven by new biotechnologies and nanotechnologies. Emerging delivery technologies, such as electroporation (EP), innovative vaccine formats like mRNA preventive boost, and new molecular adjuvant technologies are particularly important for mRNA vaccines reaching their potential.